Literature DB >> 6488501

Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure.

R D Magorien, C V Leier, A J Kolibash, T J Barbush, D V Unverferth.   

Abstract

Rest and exercise systemic hemodynamic parameters, coronary blood flow, and myocardial energetics were assessed before and 15 min after the sublingual administration of 20 mg of nifedipine in 10 patients with idiopathic congestive cardiomyopathy. When compared with control, nifedipine increased rest and exercise cardiac index by 37% and 28%, respectively (p less than .001). Peripheral vasodilation was demonstrated with a drop in systemic arterial pressure, exercise pulmonary capillary wedge pressure, and systemic vascular resistance (p less than .05). The calcium-channel blocker did not alter myocardial oxygen consumption; however, coronary blood flow increased by 32% at rest (p less than .01) while coronary vascular resistance diminished both at rest and after exercise compared with control (p less than .05). Nifedipine elicited a decrease in the rest and exercise aortocoronary sinus oxygen difference while the coronary sinus oxygen saturation increased (p less than .01). In this group of patients with idiopathic congestive cardiomyopathy, nifedipine enhanced myocardial performance while increasing coronary blood flow and favorably altering the myocardial oxygen supply-demand balance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488501     DOI: 10.1161/01.cir.70.5.884

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.

Authors:  A Ferro; M Salvatore; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

2.  Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats.

Authors:  Fumio Ohta; Tomo Takagi; Hiroyuki Sato; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Calcium antagonists and chronic cardiac failure.

Authors:  M J Kendall; R C Horton; S R Smith
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 5.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

6.  Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.

Authors:  I P Mulligan; A G Fraser; M J Lewis; A H Henderson
Journal:  Br Heart J       Date:  1989-01

7.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

8.  Modification of pacing-induced alterations in diastolic properties of the regional myocardium by nifedipine in patients with coronary artery disease.

Authors:  H Nonogi; S Sasayama; S Miyazaki; H Asanoi; K Yamanishi; C Kawai; S Eiho; M Kuwahara
Journal:  Heart Vessels       Date:  1985-11       Impact factor: 2.037

Review 9.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 10.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.